Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service cervical fusion & disc arthroplasty cases in Rhode Island: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (210 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 0 | 118 | 51% |
| 2020 | 1 | 130 | 53% |
| 2021 | 1 | 136 | 57% |
| 2022 | 3 | 124 | 60% |
| 2023 | 0 | 123 | 64% |
| 2024 | 0 | 112 | 66% |
| 2025 from claims | – | 157 127–184 | 67% |
| 2026 forecast | – | 170 133–213 | 66% |
| 2027 forecast | – | 179 132–236 | 66% |
| 2028 forecast | – | 188 133–259 | 67% |
| 2029 forecast | – | 198 134–284 | 67% |
| 2030 forecast | – | 208 136–309 | 67% |
ACDF, posterior cervical fusion, cervical total disc replacement. Professional codes (what the surgeon bills): CPT 22551, 22600, 22856; the hospital bills MS-DRG 471, 472, 473, 429, 430.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% inpatient hospital.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
No metro breakdown yet.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 35 | 1,875−1.6%/yr | −1.6%/yr | 1.0 | 2% | 1,980 in 2030+0.9%/yr |
| Pennsylvania | 23 | 1,803−4.6%/yr | −4.6%/yr | 1.3 | 0% | 1,920 in 2030+1%/yr |
| Massachusetts | 23 | 1,163−2.2%/yr | −2.2%/yr | 1.2 | 0% | 1,360 in 2030+2.6%/yr |
| New Jersey | 15 | 957+0.5%/yr | +0.5%/yr | 0.9 | 0% | 1,050 in 2030+1.5%/yr |
| Connecticut | 4 | 398−6.3%/yr | −6.3%/yr | 1.2 | 0% | 400 in 2030+0.2%/yr |
| New Hampshire | 2 | 171−9.5%/yr | −9.5%/yr | 0.7 | 0% | 180 in 2030+0.7%/yr |
| Maine | 0 | 110−11%/yr | −11%/yr | 0.7 | 0% | 160 in 2030+6.5%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Decompression & minimally invasive spine | 10 | 326−4.7%/yr | −4.7%/yr | 3.41.3× | 0% | 340 in 2030+0.7%/yr |
| Lumbar fusion | 8 | 294−2.1%/yr | −2.1%/yr | 3.11.5× | 0% | 460 in 2030+7.8%/yr |
Cervical fusion & disc arthroplasty in every state, and its device makers · Every procedure market in Rhode Island · Every state · Compare with New York
Globus Medical leads with 47% of company spending on these surgeons in 2025, +41 pts on 2024.
In 2025, 7 companies reported engagement with Rhode Island’s surgeons worth $55K in consulting, speaking, meals and travel tied to these products. Royalties are left out.
FDA, last 12 months: 69 clearances and approvals in the category, 4 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.